Altus Wealth Group’s Biogen BIIB Stock Holding History

Altus Wealth Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10	Closed	-$2K	–	230
2020 Q4	$2K	Buy	+10	New	+$2.58K	﹤0.01%	735

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Altus Wealth Group's BIIB Position: Q1 2021 in Review

Altus Wealth Group sold out of Biogen (BIIB) in Q1 2021, closing a stake of 10 shares — an estimated $2K sold.

Altus Wealth Group first reported a position in BIIB in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 1,093 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

Altus Wealth Group reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
Altus Wealth Group sold 10 Biogen shares in Q1 2021, an estimated $2K.
Altus Wealth Group first reported a position in Biogen in Q4 2020 and held it in 1 quarter.
Altus Wealth Group's Biogen position peaked at $2K in Q4 2020.
1,093 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Altus Wealth Group's 13F filing for Q1 2021, filed 14 May 2021.